

MULTIPLE SCLEROSIS REFERRAL FORM

Please complete the following and fax with clinical documentation to: 720.870.2414

		R	eferral Process			
1. PATIENT INFORMATION			2. PHYSICIAN INFORMATION			
Name:			Physician's name:			
Address:			License #: NPI #:			
City:	State:	Zip:	DEA #:			
Home Phone:	Other Pho	one:	Address:			
Email:			City: State: Zip:			
DOB:	Social Security #:		Office Contact:			
Gender: M	F Height:	Weight:	Phone: Fax:			
Allergies:						
 3. DIAGNOSIS: G35 Multiple Sclerosis Has the patient been previously treated for this condition?			Last MRI date: Any Changes? Yes No SCr: CrCL: TB Test: Positive Negative Hepatitis B virus screening: Yes No Novantrone®: Is patients LVEF <50% Yes No Infuse 12mg/m2 every 3 months What is the lifetime (cumulative) Novantron® dose?mg/m2 Please provide a copy of last CBC w/ diff.; date If Kesimpta® prescribed, provide quantitative serum IG screening Is patient pregnant or nursing Yes No he front and back of primary and secondary insurance cards with this			
☐ Ocrevus [™]	300mg/10ml vial*	☐ Initial dosing:	Infuse 300 mg IV as directed followed two (2)	4 week		
Gereves	Jooning/ Torrii vidi	weeks later by a Subsequent d months *Each 300 mg	second 300 mg IV dose osing: Infuse 600 mg IV as directed every six (6) g dose must be diluted in 250 mls of 0.9% ide for injection	supply	refills	
☐ Kesimpta®	20 mg Prefilled	☐ Initial Dosing	: 20 mg SC administered at Week 0, 1, and 2	4 week		
	Syringe 20 mg Pen	Subsequent D	Posing: 20 mg SC administered monthly starting	supply	refills	
☐ Tysabri®	300mg/15ml vial*	Infuse 300 mg IV over 1 hour every 4 weeks *Each 300 mg must be diluted in 100 mls of 0.9% Sodium Chloride for injection		4 week supply	refills	
Avonex®	30mcg Prefilled Syringe #4	Inject 30mcg IM Week 1: 7.5mcg Week 2: 15mcg	(0.125ml) IM (0.25ml) IM	4 week supply	refills	
	30mcg Pen #4	Week 3: 22.5 mg Week 4: 30mcg				

Betaseron®	0.3mg vial	Dose Titration: Weeks 1-2: inject 0.0625mg/0.25ml SQ every other day	4 week supply	refills
☐ Extavia®	0.3mg vial	Weeks 3-4: inject 0.0825mg/0.25ml SQ every other day Weeks 3-4: inject 0.125mg/0.50ml SQ every other day Weeks 5-6: inject 0.1875mg/0.75ml SQ every other day Weeks 7+: inject 0.25mg/1ml SQ every other day Maintenance: inject 0.25mg/1ml SQ every other day		remis
Copaxone®	20mg Prefilled Syringe	20mg SQ daily	4 week supply	refills
	40mg Prefilled Syringe	☐ 40mg SQ 3 times per week	Зорріу	Terms
☐ Gilenya®	0.5mg capsules	0.5 mg po once-daily in adults and pediatric patients 10 years of age and older weighing more than 40 kg	4 week supply	refills
	0.25mg capsules	0.25 mg po once daily in pediatric patients 10 years of age and older weighing less than or equal to 40 kg		
Rebif®	8.8mcg Prefilled	☐ Weeks 1-2: inject 8.8mcg SQ three times per week☐ Weeks 3-4: inject 22mcg SQ three times per week	4 week supply	refills
	Autoinjector 22mcg Prefilled	Weeks 5+: (48 hrs apart): inject 44mcg SQ three times per week		
	Syringe or Autoinjector		4 week supply	refills
	44mcg Prefilled	Week 1-2: inject 4.4mcg (0.1ml) SQ three times per week	зорріу	Tellis
	Syringe or Autoinjector	☐ Week 3-4: inject 11mcg (0.25ml) SQ three times per week ☐ Maintenance: inject 22mcg (0.5ml) SQ three times per week		
	thylprednisolone cribers Office	Diphenhydramineient's Home Injection Training completed by:		
6. FLUSH ORDE PIV/midline/PICC		ach infusion, and as needed with 3-20 ml NS, followed by Heparin	2-5 ml if inc	licated
Port: Flush before		and as needed with 5-20 ml NS, followed by Heparin 100 unit/ml 5	ml.	
For severe react	d reaction-administer di	iphenhydramine 50mg IVP/PO x 1. ohrine 0.3mg SubQ/IM x 1. May repeat x1 if needed. Contact 911 c	and monitor	vital
Age 1-5 : 12.	.5mg IV/PO x1	d reaction (rash/hives) give diphenhydramine Age 6-11: 25mg IV/PO x1 Age 12+: 50mg IV/PO x1		
		Iminister epinephrine. 0.01 mg/kg/dose (max 0.3 mg) SubQ/IM x $1.$ - 10 minutes for a maximum of two doses. Contact 911 and monitor	vital signs.	
Labs:		on Permitted		
PHYSICIAN'S SIGNATURE (required):				

www.veroshealth.com
© Veros Health. All rights reserved. 03.23
Prescription is valid for one year unless otherwise indicated. The prescriber is to comply with his/her state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.